Chemotherapy Response Score in Ovarian Cancer with Alejandra Martinez
In this episode of the IJGC podcast, Editor-in-Ch…
BMJ talk medicine · BMJ Group
August 1, 202232m 47s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Professor Alejandra Martinez to discuss the Chemotherapy Response Score (CRS) in ovarian cancer. Prof. Martinez has been the Deputy Head of the Surgical Oncology Department at Toulouse University Cancer Center (Institut Universitaire du Cancer de Toulouse) since 2016. She has served as the Director of the ESGO fellowship program of the IUCTO since 2017 and as a professor in oncology since 2021.
Highlights:
- CRS is an easy and reproductible biomarker that can help to stratify a patient's treatment.
- CRS 1-2 is associated with higher tumor load, more extensive surgical procedures, residual tumor after cytoreduction, and early relapse.
- Pathology response measured by the CRS is associated with disease-free and overall survival in patients with stage IIIC/IV treated with neoadjuvant chemotherapy irrespective of the number of cycles.